Journal: Journal of Cellular and Molecular Medicine

Article Title: E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases

doi: 10.1111/j.1582-4934.2008.00548.x

Figure Lengend Snippet: (A) LYVE-1-positive lymphatic vessels in orthotopic tumours received the different treatment. Representative images were shown (×200). (B) Serum endostatin levels in the mice with orthotopic tumours. After systemic delivery of E10A, serum endostatin levels were determined by ELISA. Serum endostatin levels in mice treated with Ad-LacZ were used as control. (C) Serum VEGF levels in different groups of mice. Mice were killed after 4 weeks of treatment and serum were collected for determination of VEGF levels by ELISA. Columns, mean ± S.D. * P < 0.05, compared with Ad-LacZ control.

Article Snippet: The supernatants of PC-3 cells after 72 hrs of infection with E10A or Ad-LacZ at MOI of 100 were harvested as conditioned medium (CM) and evaluated endostatin protein using a human endostatin ELISA kit (R&D systems, Minneapolis, MN, USA) according to the recommendation of the manufacturer.

Techniques: Enzyme-linked Immunosorbent Assay, Control

Journal: BMC Cancer

Article Title: Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

doi: 10.1186/s12885-024-12001-6

Figure Lengend Snippet: Baseline and clinical characteristics of patients and their correlation with Endostar

Article Snippet: Tanabe et al [ ] found that endostatin suppressed peritoneal fibrosis by significantly reducing vascular endothelial growth factor A (VEGF-A), alpha-smooth muscle actin (α-SMA), and the pro-fibrotic factor TGF-β1 in a mouse model. Another investigation revealed that Endostar alleviated radiation-induced pulmonary alveolitis, pulmonary edema, fibrosis, and TGF-β1 release in mice compared to radiation-exposed mice treated without Endostar, suggesting that Endostar can reduce radiation-induced pulmonary lesions [ ].

Techniques:

Journal: BMC Cancer

Article Title: Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

doi: 10.1186/s12885-024-12001-6

Figure Lengend Snippet: The difference in the incidence of ≥ grade 2 RP at different subgroups

Article Snippet: Tanabe et al [ ] found that endostatin suppressed peritoneal fibrosis by significantly reducing vascular endothelial growth factor A (VEGF-A), alpha-smooth muscle actin (α-SMA), and the pro-fibrotic factor TGF-β1 in a mouse model. Another investigation revealed that Endostar alleviated radiation-induced pulmonary alveolitis, pulmonary edema, fibrosis, and TGF-β1 release in mice compared to radiation-exposed mice treated without Endostar, suggesting that Endostar can reduce radiation-induced pulmonary lesions [ ].

Techniques:

Journal: BMC Cancer

Article Title: Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

doi: 10.1186/s12885-024-12001-6

Figure Lengend Snippet: The efficacy of endostar with NSCLC in previously reported studies

Article Snippet: Tanabe et al [ ] found that endostatin suppressed peritoneal fibrosis by significantly reducing vascular endothelial growth factor A (VEGF-A), alpha-smooth muscle actin (α-SMA), and the pro-fibrotic factor TGF-β1 in a mouse model. Another investigation revealed that Endostar alleviated radiation-induced pulmonary alveolitis, pulmonary edema, fibrosis, and TGF-β1 release in mice compared to radiation-exposed mice treated without Endostar, suggesting that Endostar can reduce radiation-induced pulmonary lesions [ ].

Techniques: Control

Journal: BMC Cancer

Article Title: Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

doi: 10.1186/s12885-024-12001-6

Figure Lengend Snippet: Clinical trials about Endostar combined with ICIs in NSCLC

Article Snippet: Tanabe et al [ ] found that endostatin suppressed peritoneal fibrosis by significantly reducing vascular endothelial growth factor A (VEGF-A), alpha-smooth muscle actin (α-SMA), and the pro-fibrotic factor TGF-β1 in a mouse model. Another investigation revealed that Endostar alleviated radiation-induced pulmonary alveolitis, pulmonary edema, fibrosis, and TGF-β1 release in mice compared to radiation-exposed mice treated without Endostar, suggesting that Endostar can reduce radiation-induced pulmonary lesions [ ].

Techniques: Clinical Proteomics

Journal: Oncology Reports

Article Title: Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer

doi: 10.3892/or.2012.1828

Figure Lengend Snippet: MET CPA combined with Endostar inhibits the growth of xenograft tumors in mice. BALB/c nude mice were inoculated subcutaneously with human NSCLC A549 cells and when a palpable tumor developed, mice were randomly assigned into five groups (n=15 for the Ctrl, MET CPA, Endo, MET CPA + Endo groups; n=14 for the MTD CPA group). The tumor volumes of different groups were compared at indicated time-points. Data shown are mean ± SD of tumor volumes in individual groups of mice. ** P<0.01 vs. the Ctrl group; # P<0.05, ## P<0.01 vs. the MET CPA + Endo group.

Article Snippet: Endostar was obtained from Simcere Pharmaceutical Group (Nanjing, China) and cyclophosphamide monohydrate (CPA) was purchased from International Laboratory (San Bruno, CA, USA).

Techniques:

Journal: Oncology Reports

Article Title: Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer

doi: 10.3892/or.2012.1828

Figure Lengend Snippet: MET CPA combined with Endostar decreases the frequency of peripheral blood total and viable CECs. The frequency of peripheral blood total and viable CECs in individual mice was determined by flow cytometry analysis. Peripheral blood nuclear cells were stained with APC-anti-CD45, PE-anti-CD146 and 7AAD. (A) The cells were gated on FSC vs. SSC plot. (B) The CD45 − CD146 + CECs were selected. (C) To distinguish 7AAD + apoptotic CECs from 7AAD − viable ones. The frequency of peripheral blood total (D) and viable CECs (E) in individual groups of mice was quantitatively analyzed. Data are expressed as mean ± SD of the frequency of peripheral blood CECs in individual groups (n=8 per group). ** P<0.01 vs. the Ctrl group; # P<0.05, ## P<0.01 vs. the MET CPA + Endo group.

Article Snippet: Endostar was obtained from Simcere Pharmaceutical Group (Nanjing, China) and cyclophosphamide monohydrate (CPA) was purchased from International Laboratory (San Bruno, CA, USA).

Techniques: Flow Cytometry, Staining

Journal: Oncology Reports

Article Title: Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer

doi: 10.3892/or.2012.1828

Figure Lengend Snippet: MET CPA combined with Endostar reduces tumor MVD. The MVD in xenograft tumors from different groups of mice was determined by immunofluorescence staining with anti-CD31 antibody. (A) Representative images of immunofluorescence staining of endothelial cells in tumor tissues from different groups of mice. (B) Quantifications of MVD. Data are expressed as mean ± SD of the MVD value of individual groups (n=8 per gorup). ** P<0.01 vs. the Ctrl group; ## P<0.01 vs. the MET CPA + Endo group.

Article Snippet: Endostar was obtained from Simcere Pharmaceutical Group (Nanjing, China) and cyclophosphamide monohydrate (CPA) was purchased from International Laboratory (San Bruno, CA, USA).

Techniques: Immunofluorescence, Staining

Journal: Oncology Reports

Article Title: Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer

doi: 10.3892/or.2012.1828

Figure Lengend Snippet: MET CPA combined with Endostar reduces pericyte coverage in xenograft tumors but not in livers. The pericyte coverage in xenograft tumors and livers from individual groups of mice was characterized by immunofluorescence staining with anti-NG2 antibody (green), anti-CD31 antibody (red) and DAPI (blue). (A) Representative images of microvessels in the tumors (top panels) and livers (lower panels) from different groups of mice. (B) Quantifications of pericyte coverage in the tumors from different groups of mice. Data are expressed as mean ± SD of the percent of pericyte coverage in individual groups (n=8 per group). There was no significant difference in pericyte coverage in livers of different groups of mice (data not shown). * P<0.05, ** P<0.01 vs. the Ctrl group; ## P<0.01 vs. the MET CPA + Endo group.

Article Snippet: Endostar was obtained from Simcere Pharmaceutical Group (Nanjing, China) and cyclophosphamide monohydrate (CPA) was purchased from International Laboratory (San Bruno, CA, USA).

Techniques: Immunofluorescence, Staining

Journal: Oncology Reports

Article Title: Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer

doi: 10.3892/or.2012.1828

Figure Lengend Snippet: MET CPA combined with Endostar prolonges survival of tumor-bearing mice. Following inoculation with the tumor, survival of individual mice was monitored up to 37 weeks after treatment. Data are shown as survival probability and the difference among groups was determined by log-rank test (n=15 for the control, MET CPA, Endo, MET CPA + Endo groups; n=14 for the MTD CPA group). * P<0.05, ** P<0.01 vs. the Ctrl group; # P<0.05 vs. the MET CPA + Endo group.

Article Snippet: Endostar was obtained from Simcere Pharmaceutical Group (Nanjing, China) and cyclophosphamide monohydrate (CPA) was purchased from International Laboratory (San Bruno, CA, USA).

Techniques: Control

Journal: Frontiers in Medicine

Article Title: Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma

doi: 10.3389/fmed.2024.1463041

Figure Lengend Snippet: Patient general information.

Article Snippet: Kisker ( ) found that after a single intraperitoneal injection of Endostar to mice, the drug in the tumor tissue was quickly cleared within 2 h. Moreover, continuous administration through a micro-osmotic pump can keep the blood drug concentration stable for a long time, and the same anti-tumor effect can be obtained with one-eighth of the dose of a single injection.

Techniques:

Journal: Frontiers in Medicine

Article Title: Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma

doi: 10.3389/fmed.2024.1463041

Figure Lengend Snippet: Comparison of short-term efficacy among three groups.

Article Snippet: Kisker ( ) found that after a single intraperitoneal injection of Endostar to mice, the drug in the tumor tissue was quickly cleared within 2 h. Moreover, continuous administration through a micro-osmotic pump can keep the blood drug concentration stable for a long time, and the same anti-tumor effect can be obtained with one-eighth of the dose of a single injection.

Techniques: Comparison

Journal: Frontiers in Medicine

Article Title: Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma

doi: 10.3389/fmed.2024.1463041

Figure Lengend Snippet: Progression-free survival curve of ENDOSTAR continuous infusion group, ENDOSTAR intravenous drip group and concurrent chemotherapy group. The curves depict the rates at which patients in each group maintained disease progression-free status over time since the commencement of treatment.

Article Snippet: Kisker ( ) found that after a single intraperitoneal injection of Endostar to mice, the drug in the tumor tissue was quickly cleared within 2 h. Moreover, continuous administration through a micro-osmotic pump can keep the blood drug concentration stable for a long time, and the same anti-tumor effect can be obtained with one-eighth of the dose of a single injection.

Techniques: Biomarker Discovery

Journal: Frontiers in Medicine

Article Title: Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma

doi: 10.3389/fmed.2024.1463041

Figure Lengend Snippet: The overall survival curve of ENDOSTAR continuous infusion group, ENDOSTAR intravenous drip group and concurrent chemotherapy group. The curves reflect the survival conditions of patients in each group from the start of treatment until the end of follow-up.

Article Snippet: Kisker ( ) found that after a single intraperitoneal injection of Endostar to mice, the drug in the tumor tissue was quickly cleared within 2 h. Moreover, continuous administration through a micro-osmotic pump can keep the blood drug concentration stable for a long time, and the same anti-tumor effect can be obtained with one-eighth of the dose of a single injection.

Techniques:

Journal: Frontiers in Medicine

Article Title: Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma

doi: 10.3389/fmed.2024.1463041

Figure Lengend Snippet: The adverse reactions of 62 cases of esophageal carcinoma with different therapeutic schemes.

Article Snippet: Kisker ( ) found that after a single intraperitoneal injection of Endostar to mice, the drug in the tumor tissue was quickly cleared within 2 h. Moreover, continuous administration through a micro-osmotic pump can keep the blood drug concentration stable for a long time, and the same anti-tumor effect can be obtained with one-eighth of the dose of a single injection.

Techniques:

Journal: American Journal of Cancer Research

Article Title: Anticancer therapeutics: a brief account on wide refinements

doi:

Figure Lengend Snippet: List of anti-angiogenic drugs approved by the FDA for the treatment of cancer

Article Snippet: Hairy Cell Leukemia, Malignant Melanoma, Follicular Lymphoma, AIDS-Related Kaposi’s Sarcoma Lenalidomide (Revlimid ® ), Celgene Non-small cell lung cancer (NSCLC) Thalidomide (Thalomid ® , Celgene metastatic colorectal cancer TAS-102 (Lonsurf ® ), Taiho multiple myeloma rhEndostatin (Endostar/Endu-available only in China), Simcere Alitretinoin (Panretin ® ) Imiquimod (Aldara ® ) Polyphenon E (Veregen ® ) Vismodegib (Eviredge, Genentech) Sonidegib (Odomzo, Novartis) Open in a separate window List of anti-angiogenic drugs approved by the FDA for the treatment of cancer Photodynamic therapy (PDT) Photodynamic therapy is a minimally invasive, dual selective and clinically approved therapeutic procedure for cancer treatment [ 200 , 201 ].

Techniques: Bioprocessing, Recombinant

Journal: Gene therapy

Article Title: Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer

doi: 10.1038/gt.2009.74

Figure Lengend Snippet: A , VVlacZ and VVhEA construction by insertion of the lacZ and human endostatin-angiostatin fusion genes respectively into the Not1 restriction site of VVLister; B , Potency of VVhEA and VVLacZ in human pancreatic cancer cell lines. EC50 values + SEM calculated by MTS assay 144 hours after infection with different vaccinia viruses; C and D , Replication of recombinant viruses in pancreatic cell lines infected with 1 PFU/cell VVlacZ or VVhEA. Mean viral replication ± SEM was determined by TCID 50 assay.

Article Snippet: Human endostatin levels in the plasma of BALB/c nu/nu mice bearing Suit-2 xenografts treated with IV VVhEA, VVlacZ or PBS were obtained using the Duoset ® ELISA for human endostatin (R and D Systems, Abingdon, UK unless otherwise stated) according to the manufacturers' instructions.

Techniques: MTS Assay, Infection, Recombinant

Journal: Gene therapy

Article Title: Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer

doi: 10.1038/gt.2009.74

Figure Lengend Snippet: A , Endostatin-angiostatin fusion protein expression in Suit-2 cells. Suit-2 cells were infected with 1 PFU/cell of VVhEA or VVlacZ. Cells and supernatant were harvested 24, 48 and 72 hours later. Western blots were performed as described in Materials and Methods. All fusion protein bands were between 70 and 80 kDa and β actin around 45 kDa. Although intracellular transgene expression was found in the cells by 24 hours following infection, endostatin-angiostatin fusion protein was detected in the supernatant only after 48 hours; B and C , Inhibition of HUVEC tube formation. HUVEC were seeded in Matrigel with 10μg of supernatant harvested and concentrated 72 hours after Suit-2 cells were infected with 1 PFU/cell of VVhEA or VVlacZ. 16 hours later, 400 μg Calcein AM was added and fluorescence microscopy used to assess the number of fully formed HUVEC tubes, which were compared to mock-infected controls and each other by one-way ANOVA; D , Inhibition of HUVEC proliferation, Mean cell survival ± SEM as a percentage of uninfected HUVEC by MTS assay 96 hours post-treatment with 10μg/ml of supernatant harvested from Suit-2 cells infected with 1 PFU/cell of VVhEA or VVlacZ for 72 hours. Mean results were compared by one-way ANOVA with Bonferonni post-hoc testing.

Article Snippet: Human endostatin levels in the plasma of BALB/c nu/nu mice bearing Suit-2 xenografts treated with IV VVhEA, VVlacZ or PBS were obtained using the Duoset ® ELISA for human endostatin (R and D Systems, Abingdon, UK unless otherwise stated) according to the manufacturers' instructions.

Techniques: Expressing, Infection, Western Blot, Inhibition, Fluorescence, Microscopy, MTS Assay

Journal: Gene therapy

Article Title: Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer

doi: 10.1038/gt.2009.74

Figure Lengend Snippet: A , IHC for Lister vaccinia virus coat protein and human endostatin was performed on Suit-2 tumors; B , ELISA for human endostatin performed on plasma harvested from animals after 1×10 7 PFU IV VVhEA or VVlacZ with representative images at 48 and 480 hours (X200); C and D, IHC for murine CD31 to assess mean microvessel density± SEM in 5 random x200 fields of IT (C) or IV (D) VVhEA-, VVlacZ- or PBS-treated tumors compared by t tests.

Article Snippet: Human endostatin levels in the plasma of BALB/c nu/nu mice bearing Suit-2 xenografts treated with IV VVhEA, VVlacZ or PBS were obtained using the Duoset ® ELISA for human endostatin (R and D Systems, Abingdon, UK unless otherwise stated) according to the manufacturers' instructions.

Techniques: Virus, Enzyme-linked Immunosorbent Assay, Clinical Proteomics